Literature DB >> 25684965

Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

A Boudewijn de Vries1, Marcel Janse1, Hans Blokzijl1, Rinse K Weersma1.   

Abstract

AIM: To review the current literature for the specific clinical characteristics of inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC).
METHODS: A systematical review for clinical characteristics of IBD in PSC was performed by conducting a broad search for "primary sclerosing cholangitis" in Pubmed. "Clinical characteristics" were specified into five predefined subthemes: epidemiology of IBD in PSC, characteristics of IBD in PSC (i.e., location, disease behavior), risk of colorectal cancer development, IBD recurrence and de novo disease after liver transplantation for PSC, and safety and complications after proctocolectomy with ileal pouch-anal anastomosis. Papers were selected for inclusion based on their relevance to the subthemes, and were reviewed by two independent reviewers. Only full papers relevant to PSC-IBD were included. Additionally the references of recent reviews for PSC (< 5 years old) were scrutinized for relevant articles.
RESULTS: Initial literature search for PSC yielded 4704 results. After careful review 65 papers, comprising a total of 11406 PSC-IBD patients, were selected and divided according to subtheme. Four manuscripts overlapped and were included in two subthemes. Prevalence of IBD in PSC shows a large variance, ranging from 46.5% to 98.7% with ulcerative colitis (UC) being the most common type (> 75%). The highest IBD rates in PSC are found in papers reviewing both endoscopic and histological data for IBD diagnosis. Although IBD in PSC is found to be a quiescent disease, pancolitis occurs often, with rates varying from 35% to 95%. Both backwash ileitis and rectal sparing are observed infrequently. The development of dysplasia or colorectal carcinoma is increased in PSC-IBD; the cumulative 10 years risk varying between 0% and 11%. Exacerbation of IBD is common after liver transplantation for PSC and de novo disease is seen in 1.3% to 31.3% of PSC-IBD patients. The risk for development of pouchitis in PSC-IBD is found to be significant, affecting 13.8% to 90% of the patients after proctocolectomy with ileo anal-pouch anastomosis.
CONCLUSION: IBD in primary sclerosing cholangitis represents a distinct phenotype that differs from UC and Crohn's disease and therefore requires specialized management.

Entities:  

Keywords:  Clinical characteristics; Incidence; Inflammatory bowel disease; Liver transplantation; Pouchitis; Primary sclerosing cholangitis; Risk of colorectal carcinoma

Mesh:

Year:  2015        PMID: 25684965      PMCID: PMC4323476          DOI: 10.3748/wjg.v21.i6.1956

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  109 in total

1.  The development of carcinoma of the large intestine in ulcerative colitis.

Authors:  I M DAWSON; J PRYSE-DAVIES
Journal:  Br J Surg       Date:  1959-09       Impact factor: 6.939

2.  Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Hitoshi Sano; Takahiro Nakazawa; Tomoaki Ando; Kazuki Hayashi; Itaru Naitoh; Fumihiro Okumura; Katsuyuki Miyabe; Michihiro Yoshida; Satoru Takahashi; Hirotaka Ohara; Takashi Joh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-03       Impact factor: 7.027

3.  Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan.

Authors:  Atsushi Tanaka; Susumu Tazuma; Kazuichi Okazaki; Hirohito Tsubouchi; Kazuo Inui; Hajime Takikawa
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-10-29       Impact factor: 7.027

4.  Primary sclerosing cholangitis in Japan--analysis of 192 cases.

Authors:  H Takikawa; T Manabe
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

5.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

6.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

7.  Risk factors in primary sclerosing cholangitis.

Authors:  E Schrumpf; M Abdelnoor; O Fausa; K Elgjo; E Jenssen; F Kolmannskog
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

8.  Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver.

Authors:  A Escorsell; A Parés; J Rodés; J A Solís-Herruzo; M Miras; E de la Morena
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

Review 9.  Primary sclerosing cholangitis--what is the difference between east and west?

Authors:  Ali Shorbagi; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

10.  Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship.

Authors:  Emmanouil Sinakos; Sunil Samuel; Felicity Enders; Edward V Loftus; William J Sandborn; Keith D Lindor
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more
  43 in total

1.  Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.

Authors:  Henry Shiau; Faith D Ihekweazu; Mansi Amin; Tatiana Fofanova; Tamir Miloh; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-10       Impact factor: 2.839

Review 2.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

Review 3.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

4.  Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.

Authors:  Noa Krugliak Cleveland; David T Rubin; John Hart; Christopher R Weber; Katherine Meckel; Anthony L Tran; Arthur S Aelvoet; Isabella Pan; Alex Gonsalves; John Nick Gaetano; Kelli M Williams; Kristen Wroblewski; Bana Jabri; Joel Pekow
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 11.382

Review 5.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 6.  Management of Difficult Cases of Autoimmune Hepatitis.

Authors:  Craig Lammert; Veronica M Loy; Kiyoko Oshima; Samer Gawrieh
Journal:  Curr Gastroenterol Rep       Date:  2016-02

Review 7.  Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Authors:  Souvik Sarkar; Christopher L Bowlus
Journal:  Clin Liver Dis       Date:  2015-10-06       Impact factor: 6.126

8.  The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice.

Authors:  Nan Wu; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Julie Venter; Holly Standeford; Paolo Onori; Marco Marzioni; Domenico Alvaro; Antonio Franchitto; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Hepatology       Date:  2016-06-11       Impact factor: 17.425

Review 9.  Colitis-associated colon cancer: Is it in your genes?

Authors:  Lauren Van Der Kraak; Philippe Gros; Nicole Beauchemin
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

10.  Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.

Authors:  Ming-Hsi Wang; Omar Y Mousa; Jessica J Friton; Laura E Raffals; Jonathan A Leighton; Shabana F Pasha; Michael F Picco; Kelly C Cushing; Kelly Monroe; Billy D Nix; Rodney D Newberry; William A Faubion
Journal:  Inflamm Bowel Dis       Date:  2020-04-11       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.